Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of esomeprazole on the pharmacokinetics of regorafenib in mCRC or GIST
2015-005784-17Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regorafenib in metastatic colon cancer (mCRC) and gastrointestinal stromal tumor (GIST) (3 arms), sponsored by Erasmus MC. Primary endpoint: Regorafenib AUC with and without esomeprazole. Started Mar 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2015-005784-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005784-17.